Chronic Exposure to Hypoxia Inhibits Myelogenesis and Causes Motor Coordination Deficits in Adult Mice

Lin Chen · Shu-Yu Ren · Rui-Xue Li · Kun Liu · Jing-Fei Chen · Yu-Jian Yang · Yong-Bin Deng · Han-Zhi Wang · Lan Xiao · Feng Mei · Fei Wang

Received: 20 December 2020 / Accepted: 6 March 2021 / Published online: 22 July 2021
© The Author(s) 2021

Abstract Exposure to chronic hypoxia is considered to be a risk factor for deficits in brain function in adults, but the underlying mechanisms remain largely unknown. Since active myelogenesis persists in the adult central nervous system, here we aimed to investigate the impact of chronic hypoxia on myelination and the related functional consequences in adult mice. Using a transgenic approach to label newly-generated myelin sheaths (NG2-CreERTM; Tau-mGFP), we found that myelogenesis was highly active in most brain regions, such as the motor cortex and corpus callosum. After exposure to hypoxia (10% oxygen) 12 h per day for 4 weeks, myelogenesis was largely inhibited in the 4-month old brain and the mice displayed motor coordination deficits revealed by the beam-walking test. To determine the relationship between the inhibited myelination and functional impairment, we induced oligodendroglia-specific deletion of the transcription factor Olig2 by tamoxifen (NG2-CreERTM; Tau-mGFP; Olig2(fl/fl)) in adult mice to mimic the decreased myelogenesis caused by hypoxia. The deletion of Olig2 inhibited myelogenesis and consequently impaired motor coordination, suggesting that myelogenesis is required for motor function in adult mice. To understand whether enhancing myelination could protect brain functions against hypoxia, we treated hypoxic mice with the myelination-enhancing drug-clemastine, which resulted in enhanced myelogenesis and improved motor coordination. Taken together, our data indicate that chronic hypoxia inhibits myelogenesis and causes functional deficits in the brain and that enhancing myelogenesis protects brain functions against hypoxia-related deficits.

Keywords Chronic hypoxia · White matter · Myelogenesis · Neuro-function impairment · Clemastine

Introduction

Chronic hypoxic exposure is well recognized as a risk factor in a number of diseases in adults, such as obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), and chronic mountain sickness (CMS) [1–3]. O2-sensitive organs may be temporarily or permanently impaired by chronic hypoxia, and brain is one of the most sensitive organs [4]. Deficits in brain function have been noted during and after chronic hypoxic exposure, manifesting as motor abnormalities, impaired learning and memory and difficulties in attention [5–7]. Unfortunately, it remains largely unknown how chronic hypoxia causes these functional deficits in adults, and no effective therapies are available for preventing or reversing the functional deficits.

Clinical evidence has repeatedly shown that chronic hypoxia can induce structural changes in the adult brain. For instance, cortical atrophy and white matter tract abnormalities have been found in CMS and OSA patients, suggesting that white matter damage may coincide with the functional deficits associated with chronic
hypoxia [6, 8–10]. Myelin is an important component in CNS white matter, generated by mature oligodendrocytes (OLs). OLs project membrane-like processes and concentrically wrap axons. Myelin is not only important in insulating axons and accelerating conduction velocity, but also providing energy support to axons in the CNS [11–14]. All OLs are derived from the differentiation of oligodendrocyte precursor cells (OPCs) and this process persists throughout the lifetime [15, 16]. Myelin undergoes dynamic changes with the generation of new myelin and loss of pre-existing myelin in adults. Continuous myelin generation is important for adult brain functions, such as motor learning and spatial memory [17–21], but it remains unknown whether chronic hypoxia contributes to the inhibition of myelinoogenesis in the adult brain and causes functional deficits.

In this study, we found active myelinoogenesis was inhibited in the adult mouse brains by intermittent chronic hypoxia. The inhibition of new myelin generations impaired motor coordination, while the pro-myelination drug—clemastine treatment improved neurological functions in hypoxic adult mice. Together, these results indicate enhancing myelinoogenesis may be a potential strategy to improve chronic hypoxia-induced functional deficits in adults.

Materials and Methods

Animals

Both male and female mice on a C57BL/6 background were used in all studies. All the mice were housed in a temperature- and humidity-controlled environment with free access to standard chow and water and under a 12h/12h light/dark cycle, following to the guidelines of Third Military Medical University. All mouse strains were maintained in the Third Military Medical University specific-pathogen free animal facility. The 4-month-old adult C57BL/6 mice for hypoxia models and behavioral tests were purchased from the Laboratory Animal Center of the Third Military Medical University. The reporter gene mice, Mapt-mGFP (Tau-mGFP) (The Jackson Laboratory, catalog no. 021162), have been described previously [20]. Briefly, the line was crossed with NG2-CreERTM mice (The Jackson Laboratory, catalog no. 008538) to initiate recombination in OPCs. The Olig2 floxed line was crossed with the NG2-CreERTM; Tau-mGFP line to obtain NG2-CreERTM; Tau-mGFP; Olig2 fl/fl mice and heterozygous controls (NG2-CreERTM; Tau-mGFP; Olig2 fl/+). Another reporter gene mouse line, mt/mG line (The Jackson Laboratory, catalog no. 007676), was crossed with the PLP-CreERT line (The Jackson Laboratory, catalog no. 005795) to obtain the PLP-CreERT; mt/mG line in order to label pre-existing myelin before tamoxifen induction. The genotypes of all mice were determined using PCR analysis of tail genomic DNA with appropriate primers. All animals were fed or bred in accordance with protocols approved by the Laboratory Animal Welfare and Ethics Committee of the Third Military Medical University.

Chronic Hypoxia Model

All 4-month old animals were randomly divided into two groups. One group was placed into a hypoxia chamber (BioSpherix, ProOx P110) with the O2 concentration of 10%–11% (v/v) for 12 h every day. The exposure to hypoxia was carried out in the light phase and was sustained for 4 weeks [22–24]. The other group was kept in a normal O2 concentration (21% O2) in the same room, as normoxic controls.

Administration of Tamoxifen

To induce Cre recombination in specific cell types, tamoxifen (Sigma-Aldrich, catalog no. T5648) was dissolved in sunflower oil at 30 mg/mL and administered to mice at 100 mg/kg for 4 consecutive days by oral gavage.

Drug Treatment

Clemastine (Selleck Chemicals, Houston, TX, catalog no. S1847) was dissolved in DMSO (30 mg/mL) and diluted in the animals’ drinking water (1:20). Clemastine was finally diluted in 5% DMSO in water. The mice were treated with clemastine or an equivalent volume of vehicle (5% DMSO in water). The 4-month old hypoxic mice were given 10 mg/kg per day for 4 weeks. The mice were fed with free access to standard chow and water and under a 12h/12h light/dark cycle, following to the guidelines of Third Military Medical University.
access to standard chow and water after drug treatment everyday.

**Tissue Processing**

Each mouse was deeply anesthetized with 1% pentobarbital at 50 mg/kg and perfused with 4% paraformaldehyde in 0.1 mol/L phosphate buffer (PB; containing 0.083 mol/L Na₂HPO₄ and 0.017 mol/L NaH₂PO₄, pH 7.4) after an initial flush with 0.01 mol/L phosphate buffered saline (PBS; containing, in mmol/L, 8.3 Na₂HPO₄, 1.7 NaH₂PO₄, and 0.145 NaCl, pH 7.4). Brains were collected and postfixed with 4% paraformaldehyde in 0.1 mol/L PB overnight, then they were dehydrated in 30% sucrose in 0.01 mol/L PBS. Each brain was embedded in optimal cutting temperature compound (Sakura Finetek USA Inc., 4583) and then cut coronally at 20 µm on a cryostat microtome (CryoStar NX50, Thermo Fisher Scientific, USA). About 100 sections were collected consecutively from bregma 1.1 mm to bregma 1.34 mm. To sample in a systematic random manner, a set of 5–10 sections was sampled consecutively from each brain. In practice, every twentieth section was systematically sampled; the first was randomly selected from the first 5 sections. Floating sections were used for immunostaining.

**Immunofluorescence Staining**

For immunofluorescence staining, free floating sections were blocked with 5% bovine serum albumin and 0.2% Triton-X 100 in 0.01 mol/L PBS for 2 h at room temperature, sequentially incubated with primary antibodies overnight at 4°C, and then with fluorescent-dye-conjugated secondary antibodies for 2 h at room temperature. Primary and secondary antibodies were diluted with the blocking serum buffer. The primary antibodies were: rabbit anti-NG2 (1:500, Millipore, Cat: MAB5320), rabbit anti-NF200 (1:1000, Sigma-Aldrich, Cat: N414), rat anti-MBP (1:200, Millipore, Cat: MAB386), rabbit anti-NeuN (1:1000, Abcam, Cat: ab177487) and rat anti-CD31 (1:200, BD Biosciences, Cat: 553370). The secondary antibodies were: AlexaFluor-488-, AlexaFluor-568-, or AlexaFluor-647-conjugated antibodies against goat, rabbit or rat (1:1000; Life Technologies). Nuclei were counterstained with DAPI.

**Image Acquisition and Quantification**

Fluorescence images were captured using a confocal laser-scanning microscope (Olympus, FV3000) with excitation wavelengths appropriate for AlexaFluor-488 (488 nm), -596 (568 nm), -647 (628 nm), or DAPI (380 nm). The corpus callosum, striatum, anterior commissure (AC), hippocampus (CA1 and fimbria), motor cortex (M1 and M2), and sensory cortex (S2) were selected from each sample for quantification. The reporter gene mouse line (NG2-CreERT²; Tau-mGFP) was used to label newly-formed myelin after tamoxifen induction. mGFP-positive density was calculated using Image-Pro Plus 5.0 (Media Cybernetics).

**Behavioral Tests**

All mice were fed in a controlled environment (25°C) with free access to food and water and housed under a 12 h/12 h day/night cycle. All tests were performed between 12:00 and 18:00. After each trial, all apparatus was wiped with 30% ethanol to avoid odor cues. In all behavioral experiments, investigators were blinded to genotype and mice were handled gently to avoid stress.

**Open Field Test**

Open field tests were performed in an open-field apparatus (Biowill, Shanghai, China). Briefly, each mouse was placed in the center of the open-field box (50 × 50 × 50 cm³), then its activity was recorded for 5 min. The total distance traveled was measured to assess general motor function.

**Beam Walking Test**

A modified beam walking test was used to assess the motor coordination of mice. In the test, a beam (0.4 cm wide) was placed 50 cm above the floor in a dark room, with one end illuminated by a lamp and the other end in a non-transparent box (20 × 20 × 20 cm³). Each mouse was placed at the end with light and trained three times per day for 3 days before testing. In order to attract the mouse to walk across the beam in a sequence of 30-, 50- and 70-cm distances, padding material from its cage was placed in the
A. Behavior test/Histology

4 Months
TMF

+ 4 Weeks

Hypoxia (10% Oxygen)

B. NG2-CreER<sup>TM</sup>, Tau-mGFP

Normoxia
mGFP

Hypoxia
mGFP

C. NG2-CreER<sup>TM</sup>, Tau-mGFP

Normoxia
mGFP

Hypoxia
mGFP

D. Graph showing mGFP+ density (10<sup>4</sup>/µm<sup>2</sup>)

E. NG2/DAPI

Normoxia

Hypoxia

F. Graph showing NG2+/DAPI (%)

P = 0.461
NS

P < 0.001

P < 0.001

P = 0.461
NS
box during the training days. During the test, videos were collected from both sides of the beam to record the performance. The frequency of foot-slips when the mouse walked a distance of 80 cm was calculated as the index of beam walking performance [25].

**Statistical Analysis**

Mice were randomly assigned to experimental time points or groups, and no animals or data points were excluded from analyses. Investigators were blinded to group allocation during data collection and analysis. All data are presented as the mean ± SEM. Points represent individual animals. Statistical difference between groups was determined using the two-tailed unpaired t-test or one-way ANOVA followed by *post hoc* Tukey’s test. The statistical methods, exact n values, significant and non-significant P values, and degrees of freedom are described in the figure legends. Significance is reported as *P < 0.05, **P < 0.01, or ***P < 0.001.

**Results**

**Active Myelogenesis in Adult Mouse Brain**

We set out to map myelogenesis in the adult brain by using NG2-CreERT<sup>TM</sup>; Tau-mGFP transgenic mice. Upon recombination, newly-generated myelin sheaths and their associated OLs start to express mGFP [20, 26]. Recombination was induced in the transgenic mice at the age of 6 months and mGFP-positive myelin and mature OLs were

---

Fig. 3 Pre-existing myelin sheaths in the hypoxic adult brain. A Upper panel, schematic diagram of the time-course of hypoxic exposure, tamoxifen induction, and histology. Lower panels, representative images showing mGFP-positive areas co-localized with MBP-positive myelin sheaths in the cortex of PLP-CreERT<sup>TM</sup>; mT/mG mice, 4 weeks after recombination at 4 months. B Representative images and quantification of mGFP-positive density in the cortex of normoxic and hypoxic PLP-CreERT<sup>TM</sup>; mT/mG adult mice (n = 3 biologically independent mice per group; t<sub>4</sub> = 0.611, P = 0.574, two-tailed unpaired t-test). Points represent individual animals. Error bars represent the mean ± SEM. NS, not significant.
observed in different regions of the whole brain 4 months after induction (Fig. 1A), including the corpus callosum (Fig. 1B, B’), M2 and M1 (Fig. 1C and D), sensory cortex (Fig. 1E), caudate putamen striatum (CPu) (Fig. 1F), anterior commissure (AC) (Fig. 1G), and hippocampus (Fig. 1H and I). We calculated the density of newly-formed mGFP-positive myelin, and found that more myelin sheaths were generated in the AC and corpus callosum of adult mice (Fig. 1J). These results indicate that myelination is highly active in all brain regions in adult mice.

As pericytes are closely associated with vascular vessels in the brain and also express NG2, we investigated whether tau-mGFP is expressed in pericytes by immunostaining for CD31, a marker for vascular epithelial cells. We did not

---

**Fig. 4** Chronic hypoxia causes motor deficits in adult mice. **A** Total distance of hypoxic and normoxic mice in the open field test (n = 12 biologically independent mice per group; \( t_{(22)} = 1.019, P = 0.319, \) two-tailed unpaired \( t \)-test). **B** Mean number of foot-slips of hypoxic and normoxic mice in the beam-walking test (n = 12 biologically independent mice per group; \( t_{(22)} = 7.435, P < 0.001, \) two-tailed unpaired \( t \)-test). **C** Representative immunofluorescence images displaying NF200 expression in normoxic and hypoxic brains. **D** Quantification of NF200 density in normoxic and hypoxic brains (n = 5 biologically independent mice per group; \( t_{(8)} = 0.607, P = 0.535, \) two-tailed unpaired \( t \)-test). **E** Representative immunofluorescence images showing NeuN-positive (red) cells in normoxic and hypoxic cortex. **F** Quantification of NeuN-positive cells in normoxic and hypoxic brains (n = 5 biologically independent mice per group; \( t_{(8)} = 0.215, P = 0.835, \) two-tailed unpaired \( t \)-test). Points represent individual animals. Error bars represent the mean ± SEM. NS, not significant; ***P < 0.001.
detect Tau-mGFP positive signal on and around CD31 positive vessels (Fig. 1K), suggesting that pericytes do not express mGFP in the \textit{NG2-CreERT\textsuperscript{TM}; Tau-mGFP} mouse.

**Chronic Hypoxia Inhibits Myelogenesis in Adult Mice**

To explore the influence of chronic hypoxia on myelogenesis in adult mice, we exposed 4-month old \textit{NG2-CreERT\textsuperscript{TM}; Tau-mGFP} mice to 10\% O\textsubscript{2} (v/v) for 12 h per day. The mice were placed in a hypoxia chamber for 4-day pre-conditioning before tamoxifen induction, then the mice were randomly divided into two groups for hypoxic or normoxic exposure (Fig. 2A). After 4-weeks of exposure to hypoxia, the brains were collected for assessment of mGFP-positive new myelin. It was evident that the mGFP-positive new myelin and OLs were greatly decreased in the corpus callosum and motor cortex of the hypoxic mice compared to the normoxic controls (Fig. 2B-D). Given that myelination depends on the differentiation and maturation of OPCs, we then assessed the OPC numbers by immunostaining for NG2 to explore whether the decreased myelination induced by chronic hypoxia involved the OPC population (Fig. 2E). We calculated the ratio of NG2-positive cells to DAPI-positive nuclei and found that the percentage of NG2-positive cells did not significantly change (Fig. 2F), suggesting that chronic hypoxia inhibits OPC differentiation and myelination, rather than altering the OPC population in adult mice.

**Chronic Hypoxia Does Not Cause Significant Myelin Degeneration**

To understand whether pre-existing myelin in the brain is sensitive to hypoxia, we used the \textit{PLP-CreER\textsuperscript{T}; mT/mG} line to label pre-existing myelin [20]. The recombination driven by the \textit{plp} gene only occurs in mature OLs and their associated myelin sheaths but not in OPCs, allowing for tracing the fate of pre-existing myelin sheaths. Recombination was induced for 4 days before the mice were placed in the hypoxic chamber at the age of 4 months. The mGFP-positive myelin sheaths exclusively co-expressed myelin basic protein (MBP) as revealed by MBP immunostaining (Fig. 3A). We examined the \textit{PLP-CreER\textsuperscript{T}; mT/mG} brains after 4 weeks of exposure to hypoxia and quantified the mGFP-positive myelin sheaths in the superficial layers of cortex, where myelin is comparatively sparse. Quantification did not reveal a significant change of mGFP-positive myelin in the hypoxic brain as compared to normoxic controls (Fig. 3B), suggesting that the pre-exiting myelin is stable in response to hypoxic insult.

**Chronic Hypoxia Impairs Neuronal Functions in Adult Mice**

We next assessed whether chronic hypoxia caused functional deficits in adult mice. Open field test showed no significant difference in total distance travelled between normoxic and hypoxic mice (Fig. 4A), indicating that chronic hypoxia does not impair general activity in adults. Then we applied the modified beam-walking test to assess motor coordination in mice after chronic hypoxia [25]. We counted the total number of slips of the hind-limbs during performance of the task. The total number of slips by the hypoxic group was greater than those in the wild-type controls (Fig. 4B), suggesting that chronic hypoxia impairs neuronal function in adult mice. To determine if this functional deficit is associated with neuronal loss and axon degeneration, we immunostained for NeuN and NF200, respectively. Our results showed that the densities of NF200-positive axons and NeuN-positive neurons in chronic hypoxic brains did not significantly differ from normoxic controls (Fig. 4C-F). These results indicate that the impairments caused by chronic hypoxia unlikely to be due to significant neuronal loss or axon degeneration.

To explore whether gender differences play a role in the hypoxia-induced changes in myelogenesis and functional injury, we exposed age-matched male and female mice to 10\% O\textsubscript{2} (v/v) for 12 h per day. After 4 weeks of exposure to hypoxia, we carried out behavioral tests and the brains were collected for assessment of mGFP-positive new myelin (Fig. 5A). We found that the densities of new myelin and OLs in the cortex and corpus callosum did not significantly differ between male and female mice (Fig. 5B-D). Consistent with this, neither the open field test nor the modified beam-walking test revealed...
significant differences between male and female mice (Fig. 5E, F). These results suggest that gender differences do not bias myelogenesis and neuronal function in mice exposed to chronic hypoxia.

Inhibited Myelogenesis Impairs Neuronal function in Adults

Since hypoxia induced functional deficits and inhibited myelogenesis in adult mice, we next examined whether there is a causal relationship between inhibited myelogenesis and the deficits in motor coordination. We chose to conditionally delete Olig2 in OPCs so as to inhibit myelogenesis without affecting other cell types, as Olig2 is a transcriptional factor that is specifically expressed by oligodendroglial lineage cells and is important in regulating OPCs differentiation and myelination [27, 28]. To that end, we crossed the reporter mouse line NG2-CreERTM; Tau-mGFP with the Olig2 floxed line to obtain Olig2 conditional knockout (cKO) mice (NG2-CreERTM; Tau-mGFP; Olig2 fl/fl) and heterozygous controls (NG2-CreERTM; Tau-mGFP; Olig2 fl/þ). Tamoxifen was administered at 4 months and the mice were sacrificed 4 weeks later (Fig. 6A). We detected Olig2 expression after induction by immunostaining for Olig2 and our results indicated that the number of Olig2-positive cells was decreased greatly in the corpus callosum (Fig. 6B). Using double immunostaining for Olig2 and NG2, we also found that Olig2 expression was almost absent in NG2-positive OPCs (Fig. 5B), indicating efficient Olig2 deletion in the Olig2-cKO brain. As expected, much less newly-formed myelin (mGFP-positive) was observed in the corpus callosum, hippocampus, and motor cortex of Olig2-cKO mice than in heterozygous controls, suggesting that Olig2 deletion in OPCs mimics the decreased myelogenesis induced by chronic hypoxia (Fig. 6C-F). Again, we examined the motor coordination of Olig2-cKO mice using the beam-walking test. The results showed that there were significantly more foot slips in adult Olig2-cKO mice than that in heterozygous controls (Fig. 6G), suggesting that myelogenesis is necessary for motor coordination in adults.

Enhancing Myelination with Clemastine Prevents Hypoxia-induced Functional Deficits

Since myelogenesis is necessary for motor coordination in adults, we next explored whether enhancing OL differentiation in adults improves the functional deficits associated with chronic hypoxia. Clemastine is an FDA-approved muscarinic receptor antagonist that is effective in improving myelogenesis in vivo [29, 30]. Recombination was induced by tamoxifen treatment before hypoxia exposure. Here, we gave clemastine to 4-month-old reporter gene mice (NG2-CreERTM; Tau-mGFP) for 4 weeks, while they were exposed to chronic hypoxia (Fig. 7A). Strikingly, we found that clemastine treatment greatly increased the mGFP-positive newly-formed myelin in the motor cortex and corpus callosum (Fig. 7B-D), and the density of new myelin recovered to the same levels as in the normoxic controls, indicating that this drug enhances myelogenesis in brains exposed to chronic hypoxia. Next, we applied the beam-walking test, and found that clemastine-treated mice showed fewer foot-slips than hypoxic wild-type controls, but remained significantly more than that in normoxic mice, indicating that pathological changes other than myelogenesis are also involved in the hypoxia-related deficits (Fig. 7E). These results suggest that myelination-enhancing therapeutics may be a promising strategy to prevent hypoxia-induced impairments of neuronal function in adults.
The exact mechanisms underlying the behavioral outcomes remain unclear. It is well known that myelin sheaths insulate and nourish axons and that newly-added myelin sheaths may change the activity and gene expression of neurons. Damage to neurons and other cell types remains possible, since the enhancement of myelogenesis did not result in complete functional recovery. It is evident that the functional impairments in hypoxic adults can be caused largely by decreased myelogenesis. Notably, recent evidence has shown that myelogenesis in adulthood is required for spatial memory capacity and consolidation, as well as working memory and learning [20, 53, 54]. By using Olig2-cKO mice, we found that the inhibition of myelogenesis by Olig2 knockout in OPCs impaired motor coordination, demonstrating that inhibited myelogenesis can directly cause functional deficits in adulthood. Consistent with this, Olig2 deficiency during development also leads to myelin deficits and cognitive dysfunction [55].
neurons, so as to facilitate the establishment of neural circuitry [56–58]. Thus, it is plausible that the change in myelin substantially affected neuronal functions and this ultimately altered the behavioral outcome in hypoxic mice.

Currently, no effective therapies are available for the treatment of the neuro-functional deficits in patients with hypoxic insults. Regarding the evidence that chronic hypoxia inhibits myelogenesis and consequently disrupts neuronal functions, enhancing myelination presents a promising approach to rescuing the deficits. Here, we showed that clemastine treatment in adult mice rescued the deficits induced by chronic hypoxia. In support of this notion, clemastine also rescues the myelin damage and improves the behavioral alterations in a mouse model of Williams syndrome, and prevents the decline in memory capacity in aged mice [20, 56]. Clemastine can pass through the blood brain barrier and improved myelination and neuronal function in a clinical trial of multiple sclerosis [59]. It is not completely clear in this case that clemastine enhances myelination solely by blocking muscarinic receptor 1 (MIR), given its binding affinity to a wide range of receptors, such as histamine receptors and other muscarinic receptor subtypes [60], and it was not clear that clemastine could regulate oxygen level or Olig2 expression directly. Considering the side-effects of clemastine, ataxia and impaired coordination [61], it is necessary to develop MIR specific myelin-enhancing drugs with minimal side-effects. Nevertheless, the strategy of enhancing myelination may be of potential value in treating hypoxia-associated dysfunctions in adults.

Acknowledgements We would like to thank Dr. Richard Lu (University of Cincinnati) for the Olig2 floxed mice. This work was supported by grants from the National Natural Science Foundation of China (32000723), Chongqing Education Commission Fund (CXTQ2009), Chongqing Outstanding Young Investigator Fund (cstc2017jcjjxp0001), the Natural Science Foundation of Chongqing (cstc2017jcjAX365), the Army Medical University Natural Science Fund (31041455), and the Open Project Program of the Brain and Intelligence Research Key Laboratory of Chongqing Education Commission of China (BIR2019004).

Conflict of interest All authors claim that there are no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lévy P, Kohler M, McNicholas WT, Barbé F, McEvoy RD, Somers VK. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers 2015, 1: 1–21.
2. Wilson MH, Newman S, Imray CH. The cerebral effects of ascent to high altitudes. Lancet Neurol 2009, 8: 175–191.
3. West JB. Physiological effects of chronic hypoxia. N Engl J Med 2017, 376: 1965–1971.
4. Bailey DM. Oxygen and brain death; back from the brink. Exp Physiol 2019, 104: 1769–1779.
5. Nyakas C, Buwalda B, Luiten PG. Hypoxia and brain development. Prog Neurobiol 1996, 49: 1–51.
6. Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of sleep apnea. Physiol Rev 2010, 90: 47–112.
7. Rosenzweig I, Glasser M, Polsek D, Leschziner GD, Williams SC, Morrell MJ. Sleep apnoea and the brain: A complex relationship. Lancet Respir Med 2015, 3: 404–414.
8. Bao H, Li R, He M, Kang D, Zhao L. DTI study on brain structure and cognitive function in patients with chronic mountain sickness. Sci Rep 2019, 9: 19334.
9. Fayad N, Modrego PJ, Morales H. Evidence of brain damage after high-altitude climbing by means of magnetic resonance imaging. Am J Med 2006, 119(168): e1-168.e6.
10. Tummala S, Roy B, Park B, Kang DW, Woo MA, Harper RM, et al. Associations between brain white matter integrity and disease severity in obstructive sleep apnea. J Neurosci Res 2016, 94: 915–923.
11. Yamazaki Y. Oligodendrocyte physiology modulating axonal excitability and nerve conduction. Adv Exp Med Biol 2019, 1190: 123–144.
12. Morrison BM, Lee Y, Rothstein JD. Oligodendroglial metabotropic supports of axons. Trends Cell Biol 2013, 23: 644–651.
13. Taveggia C, Feltli ML, Wrabetz L. Signals to promote myelin formation and repair. Nat Rev Neurol 2010, 6: 276–287.
14. Pan Y, Jiang Z, Sun D, Li Z, Pu Y, Wang D, et al. Cyclin-dependent kinase 18 promotes oligodendrocyte precursor cell differentiation through activating the extracellular signal-regulated kinase signaling pathway. Neurosci Bull 2019, 35: 802–814.
15. Bercury KK, Macklin WB. Dynamics and mechanisms of CNS myelination. Dev Cell 2015, 32: 447–458.
16. Elbaz B, Popko B. Molecular control of oligodendrocyte development. Trends Neurosci 2019, 42: 263–277.
17. Bergles DE, Richardson WD. Oligodendrocyte development and plasticity. Cold Spring Harb Perspect Biol 2015, 8: a020453.
18. McKenzie IA, Ohayon D, Li H, de Faria JP, Emery B, Tohyama K, et al. Motor skill learning requires active central myelination. Science 2014, 346: 318–322.
19. Xiao L, Ohayon D, McKenzie IA, Sinclair-Wilson A, Wright JL, Fudge AD, et al. Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning. Nat Neurosci 2016, 19: 1210–1217.
20. Wang F, Ren SY, Chen JF, Liu K, Li RX, Li ZF, et al. Myelin degeneration and diminished myelin renewal contribute to age-related deficits in memory. Nat Neurosci 2020, 23: 481–486.
21. Monje M. Myelin plasticity and nervous system function. Annu Rev Neurosci 2018, 41: 61–76.
22. Bauer AT, Bürgers HF, Rabie T, Marti HH. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab 2010, 30: 837–848.
23. Sun H, Juul HM, Jensen FE. Models of hypoxia and ischemia-induced seizures. J Neurosci Methods 2016, 260: 252–260.
24. Fan J, Guang H, Zhang H, Chen D, Ding L, Fan X, et al. SIRT1 mediates apelin-13 in ameliorating chronic normobaric hypoxia-
induced anxiety-like behavior by suppressing NF-kB pathway in mice *Hippocampus*. Neuroscience 2018, 381: 22–34.

25. Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice: A user’s guide. Nat Rev Neurosci 2009, 10: 519–529.

26. Wang F, Yang YJ, Yang N, Chen XJ, Huang NX, Zhang J, et al. Enhancing oligodendrocyte myelination rescues synaptic loss and improves functional recovery after chronic hypoxia. Neuron 2018, 99: 689–701.e5.

27. Mei F, Wang HK, Liu SB, Niu JQ, Wang LY, He YT, et al. Stage-specific deletion of Olig2 opposes opposing functions on differentiation and maturation of oligodendrocytes. J Neurosci 2013, 33: 8454–8462.

28. Zhou Q, Choi G, Anderson DJ. The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuro 2001, 31: 791–807.

29. Mei F, Fancy SPJ, Shen YA, Niu J, Zhao C, Presley B, et al. Microtubular arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med 2014, 20: 954–960.

30. Mei F, Lehmann-Horn K, Shen YA, Rankin KA, Stebbins KJ, et al. Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. Elife 2016, 5: 10.

31. Duerden EG, Halani S, Ng K, Guo T, Foong J, Glass TJA, et al. Redox Biol 2019, 21: 101596.

32. Vaes JEG, Vink MA, de Theije CGM, Hoebeek FE, Benders MJNL, Nijboer CHA. The potential of stem cell therapy to repair white matter injury in preterm infants: Lessons learned from experimental models. Front Physiol 2019, 10: 540.

33. Curtis WJ, Lindeke LL, Georgieff MK, Nelson CA. Neurobehavioural functioning in neonatal intensive care unit graduates in late childhood and early adolescence. Brain 2002, 125: 1646–1659.

34. Ferriero DM. Neonatal brain injury. N Engl J Med 2004, 351: 1985–1995.

35. Woodward LJ, Anderson PJ, Austin NC, Howard K, Inder TE. Neonatal MRI to predict neurodevelopmental outcomes in preterm infants. N Engl J Med 2006, 355: 685–694.

36. Olaithé M, Bucks RS, Hillman DR, Eastwood PR. Cognitive deficits in obstructive sleep apnea: Insights from a meta-review and comparison with deficits observed in COPD, insomnia, and sleep deprivation. Sleep Med Rev 2018, 38: 39–49.

37. Biancari F, Fantacci M, Caretti A, Ronchi R, Milano G, Morel S, et al. Chronic in vivo hypoxia in various organs: Hypoxia-inducible factor-1α and apoptosis. Biochem Biophys Res Commun 2006, 342: 875–880.

38. Terraneo L, Paroni R, Biancari P, Giallongo T, Carelli S, Gorio A, et al. Brain adaptation to hypoxia and hyperoxia in mice. Redox Biol 2017, 11: 12–20.

39. Khoo MA, Pagan CM, Nallamothu T, Hevner RF, Hodge RD, Ramirez JM, et al. Intermittent hypoxia disrupts adult neurogenesis and synaptic plasticity in the dentate gyrus. J Neurosci 2019, 39: 1520–1331.

40. Tartar JL, Ward CP, McKenna JT, Thakkar M, Arrigoni E, McCarley RW, et al. Hippocampal synaptic plasticity and spatial learning are impaired in a rat model of sleep fragmentation. Eur J Neurosci 2006, 23: 2739–2748.

41. Gozal D, Row BW, Gozal E, Kheirandish L, Neville JJ, Brittain KR, et al. Temporal aspects of spatial task performance during intermittent hypoxia in the rat: Evidence for neurogenesis. Eur J Neurosci 2003, 18: 2335–2342.

42. Taivassalo T, Hussain SN. Contribution of the mitochondria to locomotor muscle dysfunction in patients with COPD. Chest 2016, 149: 1302–1312.

43. Alchanatis M, Deligjorgis N, Zias N, Amfilochiou A, Gotsis E, Karakatsani A, et al. Frontal brain lobe impairment in obstructive sleep apnoea: A proton MR spectroscopy study. Eur Respir J 2004, 24: 980–986.

44. Zhang J, Zhang H, Li J, Chen J, Han Q, Lin J, et al. Adaptive modulation of adult brain gray and white matter to high altitude: Structural MRI studies. PLoS One 2013, 8: e68621.

45. Chen X, Li H, Zhang Q, Wang J, Zhang W, Liu J, et al. Combined fractional anisotropy and subcortical volumetric abnormalities in healthy immigrants to high altitude: A longitudinal study. Hum Brain Mapp 2019, 40: 4202–4212.

46. Daulatzai MA. Evidence of neurodegeneration in obstructive sleep apnea: Relationship between obstructive sleep apnea and cognitive dysfunction in the elderly. J Neurosci Res 2015, 93: 1778–1794.

47. Chang KJ, Redmond SA, Chan JR. Remodeling myelination: Implications for mechanisms of neural plasticity. Nat Neurosci 2016, 19: 190–197.

48. Hughes EG, Orthmann-Murphy JL, Langseth AJ, Bergles DE. Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. Nat Neurosci 2018, 21: 696–706.

49. Rumajojee P, Bregman T, Miller SP, Yager JY, Fehlings MG. Rodent hypoxia-ischemia models for cerebral palsy research: A systematic review. Front Neurol 2016, 7: 57.

50. Back SA. Brain injury in the preterm infant: New horizons for pathogenesis and prevention. Pediatr Neurol 2015, 53: 185–192.

51. Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE. NG2-CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuro Nan 2010, 68: 668–681.

52. Hughes EG, Kang SH, Fukaya M, Bergles DE. Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. Nat Neurosci 2013, 16: 668–676.

53. Pan S, Mayoral SR, Choi HS, Chan JR, Kheirbek MA. Preservation of a remote fear memory requires new myelin formation. Nat Neurosci 2020, 23: 487–499.

54. Steadman PE, Xia F, Ahmed M, Mcle AF, Penning AR, Geraghty AC, et al. Disruption of oligodendrogenesis impairs memory consolidation in adult mice. Neuro 2020, 105: 150-164.e6.

55. Chen X, Wang F, Gan J, Zhang Z, Liang X, Li T, et al. Myelin deficits caused by Olig2 deficiency lead to cognitive dysfunction and increase vulnerability to social withdrawal in adult mice. Neurosci Bull 2020, 36: 419–426.

56. Barak B, Zhang Z, Liu Y, Nur A, Trangle SS, Ennis M, et al. Disruption of oligodendrocytes and the control of myelination in vivo: New insights from the rat anterior medullary velum. J Neurosci Res 2000, 59: 477–488.

57. Etxeberria A, Hokanson KC, Dao DQ, Mayoral SR, Mei F, Redmond SA, et al. Dynamic modulation of myelination in response to visual stimuli alters optic nerve conduction velocity. J Neurosci 2016, 36: 6937–6948.

58. Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, et al. Cerebral remyelination as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial. Lancet 2017, 390: 2481–2489.

59. Rodwell LT, Anderson SD, Seale JP. Inhaled clemastine, an H1 antihistamine inhibits airway narrowing caused by aerosols of non-isotonic saline. Eur Respir J 1991, 4: 1126–1134.

60. Clarke CH, Nicholson AN. Performance studies with antihistamines. Br J Clin Pharmacol 1978, 6: 31–35.